DNP - Der Neurologe & Psychiater

, Volume 18, Issue 5, pp 36–43 | Cite as

Algorithmus führt häufiger und schneller zur Response

Leitliniengerechte Pharmakotherapie der therapieresistenten Depression

Zertifizierte Fortbildung
  • 51 Downloads

Zusammenfassung

Depressionen sind häufig durch chronischen Verlauf und Therapieresistenz charakterisiert. Sowohl die Pathophysiologie der Depression als auch die Wirkweise der antidepressiven Substanzen sind noch nicht ausreichend geklärt. Die zugelassenen Antidepressiva ähneln sich in ihrer Wirklatenz und einer hohen Non-Response-Rate, im Nebenwirkungsprofil bestehen hingegen deutliche Unterschiede. Eine personalisierte Therapie steht bisher nicht zur Verfügung.

Literatur

  1. 1.
    Bschor T, Bauer M, Adli M (2014) Chronische und therapieresistente Depression. Diagnostik und Stufentherapie. Dtsch Ärztebl 111:766–776Google Scholar
  2. 2.
    Bschor T (2010) Therapy-resistant depression. Expert Rev Neurother 10:77–86CrossRefPubMedGoogle Scholar
  3. 3.
    Thase ME, Rush AJ (1997) When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58 Suppl 13:23–9PubMedGoogle Scholar
  4. 4.
    Bschor T, Kilarski LL (2016) Are antidepressants effective? A debate on their efficacy for the treatment of major depression in adults. Expert Rev Neurother 16:367–374CrossRefPubMedGoogle Scholar
  5. 5.
    Bschor T, Adli M (2008) Therapie depressiver Erkrankungen. CME-zertifizierte Fortbildung. Dtsch Ärztebl 105:782–792Google Scholar
  6. 6.
    Hiemke, C et al. (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44: 195–235CrossRefGoogle Scholar
  7. 7.
    Bschor T, Kern H, Henssler J, Baethge C (2016) Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. J Clin Psychiatry 2016 Dec 6. doi: 10.4088/JCP.16r10749. [Epub ahead of print]Google Scholar
  8. 8.
    DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg.) für die Leitliniengruppe Unipolare Depression (2015) S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression - Langfassung, 2. Auflage, Version 1, November 2015 (www.depression.versorgungsleitlinien.de)
  9. 9.
    Henssler J, Bschor T, Baethge C (2016) Combining antidepressants in acute treatment of depression: a meta-analysis of 38 studies including 4511 patients. Can J Psychiatr 61:29–43CrossRefGoogle Scholar
  10. 10.
    Ruhé HG, Huyser J, Swinkels JA, Schene AH (2006) Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry 189:309–16CrossRefPubMedGoogle Scholar
  11. 11.
    Baethge C, Heinz A, Langlitz N, Bauer M (2005) Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 255:387–400CrossRefPubMedGoogle Scholar
  12. 12.
    Crossley NA, Bauer M (2007) Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 68:935–40.CrossRefPubMedGoogle Scholar
  13. 13.
    Bschor T (2014) Lithium in the treatment of major depressive disorder. Drugs 74:855–862CrossRefPubMedGoogle Scholar
  14. 14.
    Bschor T, Berghöfer A, Ströhle A, Kunz D, Adli M, Müller-Oerlinghausen B, Bauer M (2002) How long should the lithium augmentation strategy be maintained? A 1-year follow up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol 22:427–430CrossRefPubMedGoogle Scholar
  15. 15.
    Bauer M, Bschor T, Kunz D, Berghöfer A, Ströhle A, Müller-Oerlinghausen B (2000) Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 157:1429–1435CrossRefPubMedGoogle Scholar
  16. 16.
    Nelson JC, Papakostas GI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166:980–91CrossRefPubMedGoogle Scholar
  17. 17.
    Lewitzka U. Irreversible MAO-Hemmer. In: Bschor T (Hrsg.) Behandlungsmanual therapieresistente Depression. Pharmakotherapie - somatische Therapieverfahren - Psychotherapie. Stuttgart: Kohlhammer; 2008: 102–113Google Scholar
  18. 18.
    Adli M, Pilhatsch M, Bauer M, Köberle U, Ricken R, Janssen G, Ulrich S, Bschor T (2008) Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Pharmacopsychiatry 41: 252–257CrossRefPubMedGoogle Scholar
  19. 19.
    Köhler S, Stöver LA, Bschor T (2014) MAO-Hemmer als Behandlungsoption der therapieresistenten Depression. Anwendung, Wirksamkeit und Besonderheiten. Fortschr Neurol Psychiatr 82:228–238CrossRefPubMedGoogle Scholar
  20. 20.
    Bschor T, Bauer M (1998) Schilddrüsenhormone in der Behandlung affektiver Störungen. Psychopharmakotherapie 5:94–98Google Scholar
  21. 21.
    Bauer M, Hellweg R, Gräf KJ, Baumgartner A (1998) Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 18:444–55CrossRefPubMedGoogle Scholar
  22. 22.
    Stamm TJ, Lewitzka U, Sauer C, Pilhatsch M, Smolka MN, Koeberle U, Adli M, Ricken R, Scherk H, Frye MA, Juckel G, Assion HJ, Gitlin M, Whybrow PC, Bauer M. (2014) Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 75:162–8CrossRefPubMedGoogle Scholar
  23. 23.
    Bobo WV, Voort JL, Croarkin PE, Leung JG, Tye SJ, Frye MA (2016) Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice. Depress Anxiety 33:698–710CrossRefPubMedGoogle Scholar
  24. 24.
    Adli M, Bauer M, Rush AJ (2006) Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry 59:1029–38CrossRefPubMedGoogle Scholar
  25. 25.
    Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 14:334–85CrossRefPubMedGoogle Scholar
  26. 26.
    Bauer M, Pfennig A, Linden M, Smolka MN, Neu P, Adli M (2009) Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. J Clin Psychopharmacol 29:327–33CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin 2017

Authors and Affiliations

  1. 1.Abteilung für PsychiatrieSchlosspark-KlinikBerlinDeutschland

Personalised recommendations